Inclisiran safety and efficacy in real-world clinical practice: results of a retrospective observational investigation
Abstract
BACKGROUND: Real-world data on inclisiran are limited. We report a single-centre investigation on inclisiran safety and efficacy based on concurrent lipid-lowering treatments. RESULTS: At 15 months, the mean low-density lipoprotein cholesterol (LDL-C) levels decreased by 59.5% in patients receiving statin ± ezetimibe and by 56% in those treated without statin ± ezetimibe (P < 0.001). Inclisiran with statin ± ezetimibe led to a higher likelihood of achieving LDL-C less than 55 mg/dl. Adverse effects (5.8%) were mild. MAJOR FINDINGS: This real-world study confirms inclisiran as a well tolerated and potent LDL-C-lowering treatment, with a greater efficacy when used in association with statins ± ezetimibe.
Fields of Study & Subjects
Lipoproteins and Cardiovascular Health
Diabetes
Cardiovascular Risks
and Lipoproteins
Natural Products and Biological Research
Publication details
- Journal / source
- Journal of Cardiovascular Medicine
- Publisher
- Ovid Technologies (Wolters Kluwer Health)
- Volume
- 27
- Issue
- 3
- Pages
- 249–252
- Publication date
- 23 February 2026
- Language
- EN